Atlas Trials

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Clinical trial NCT03280030 · COMPLETED

Trial details

NCT number
NCT03280030
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid Leukemia
Start date
2018-04-06
Primary completion
2022-11-14
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.